See the DrugPatentWatch profile for tigecycline

Tigecycline: A Review of its Safety Profile and Potential Liver Issues

Tigecycline, a broad-spectrum antibiotic, has been widely used to treat various infections, including those caused by resistant bacteria. However, concerns have been raised about its potential to cause liver issues. In this article, we will delve into the safety profile of tigecycline and explore the relationship between its use and liver problems.

What is Tigecycline?

Tigecycline is a glycylcycline antibiotic that was approved by the US Food and Drug Administration (FDA) in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP). It works by inhibiting protein synthesis in bacteria, making it an effective treatment option for a wide range of infections.

Liver Safety Profile of Tigecycline

Tigecycline has been associated with liver enzyme elevations, including transaminases (ALT and AST) and bilirubin. According to the FDA-approved label, the most common adverse reactions reported in clinical trials were nausea, vomiting, and diarrhea, but liver enzyme elevations were also noted.

Frequency of Liver Issues with Tigecycline Use

A study published in the Journal of Clinical Pharmacy and Therapeutics found that tigecycline was associated with a higher risk of liver enzyme elevations compared to other antibiotics. The study analyzed data from over 1,000 patients and found that 12.1% of patients treated with tigecycline experienced liver enzyme elevations, compared to 4.5% of patients treated with other antibiotics.

Risk Factors for Liver Issues with Tigecycline Use

Several risk factors have been identified for the development of liver issues with tigecycline use, including:

* Age: Older patients may be at a higher risk of developing liver issues due to decreased liver function and increased sensitivity to medications.
* Renal impairment: Patients with renal impairment may be at a higher risk of developing liver issues due to decreased clearance of the medication.
* Concurrent medications: Patients taking other medications that can cause liver damage, such as acetaminophen, may be at a higher risk of developing liver issues with tigecycline use.

Monitoring Liver Function with Tigecycline Use

Monitoring liver function is crucial when using tigecycline, especially in high-risk patients. Regular monitoring of liver enzymes, including ALT and AST, can help identify potential liver issues early on. Patients should be advised to report any symptoms of liver damage, such as nausea, vomiting, and abdominal pain, to their healthcare provider.

Conclusion

Tigecycline is a valuable antibiotic for the treatment of resistant infections, but its use should be approached with caution due to the potential for liver issues. Patients should be carefully monitored for liver enzyme elevations, and healthcare providers should consider the risk factors mentioned above when prescribing tigecycline.

Key Takeaways

* Tigecycline is associated with liver enzyme elevations, including transaminases and bilirubin.
* The frequency of liver issues with tigecycline use is higher compared to other antibiotics.
* Risk factors for liver issues with tigecycline use include age, renal impairment, and concurrent medications.
* Monitoring liver function is crucial when using tigecycline, especially in high-risk patients.

FAQs

1. What is tigecycline used to treat?

Tigecycline is used to treat complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP).

2. What are the common adverse reactions associated with tigecycline use?

The most common adverse reactions associated with tigecycline use are nausea, vomiting, and diarrhea.

3. What are the risk factors for liver issues with tigecycline use?

Risk factors for liver issues with tigecycline use include age, renal impairment, and concurrent medications.

4. How should liver function be monitored when using tigecycline?

Liver function should be monitored regularly, including the measurement of liver enzymes such as ALT and AST.

5. What should patients do if they experience symptoms of liver damage while taking tigecycline?

Patients should report any symptoms of liver damage, such as nausea, vomiting, and abdominal pain, to their healthcare provider.

Sources

1. FDA. (2005). Tygacil (tigecycline) tablets and injection. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021694s000lbl.pdf>
2. DrugPatentWatch.com. (n.d.). Tigecycline. Retrieved from <https://www.drugpatentwatch.com/drug/tigecycline>
3. Journal of Clinical Pharmacy and Therapeutics. (2018). Tigecycline and liver enzyme elevations: A systematic review and meta-analysis. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233449/>
4. European Medicines Agency. (2019). Tigecycline. Retrieved from <https://www.ema.europa.eu/en/medicines/human/EPAR/tygacil>